Targeting KRAS Directly
- 4 March 2018
- journal article
- research article
- Published by Annual Reviews in Annual Review of Cancer Biology
- Vol. 2 (1) , 81-90
Abstract
RAS proteins play a major, causal role in many human cancers. No therapies have been developed for these cancers because the RAS protein has been considered undruggable given that it has no accessible pocket to which a drug could bind with high affinity, and the mutant proteins that cause cancer are virtually identical to their essential, wild-type counterparts. New technologies in drug development, such as nuclear magnetic resonance–based fragment screening and covalent tethering, and new insights into RAS structure and function have changed this perception and facilitated the development of several drug candidates.Keywords
This publication has 34 references indexed in Scilit:
- RasIns: Genetically Encoded Intrabodies of Activated Ras ProteinsJournal of Molecular Biology, 2017
- Modular PROTAC Design for the Degradation of Oncogenic BCR‐ABLAngewandte Chemie International Edition, 2015
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS MutationsMolecular Cancer Research, 2015
- Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?Clinical Cancer Research, 2015
- GEFs and GAPs: Critical Elements in the Control of Small G ProteinsCell, 2007
- Guanosine triphosphatase stimulation of oncogenic Ras mutantsProceedings of the National Academy of Sciences, 1999
- Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function.Proceedings of the National Academy of Sciences, 1996
- The GTPase superfamily: conserved structure and molecular mechanismNature, 1991
- All ras proteins are polyisoprenylated but only some are palmitoylatedCell, 1989
- Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras proteinNature, 1985